Skip to main content

The SAMe–TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia

Journal of Thrombosis and Thrombolysis volume 50, pages 614–618 (2020)Cite this article

Abstract

Oral anticoagulation options for patients with venous thromboembolism (VTE) include vitamin K antagonists like warfarin. Good warfarin control is linked to outcomes of therapy, and the SAMe–TT2R2 model has been reported to predict control in atrial fibrillation patients with scores ≥ 2 linked to poor control. There has been limited and conflicting data in VTE populations, therefore this study aimed at determining the predictive ability of this model in Australian patients with deep vein thrombosis. Retrospective data of patients receiving warfarin care at a private pathology clinic in Queensland was collected. The time in therapeutic range (TTR) and SAMe–TT2R2 score was calculated for individual patients. Mean TTR and patients with TTR ≥ 65% were used for analysis and comparison across patients categorised as a score of 0–1 and ≥ 2. Of the 533 patients, the majority had a SAMe-TT2R2 score of 0–1. No significant difference was found in mean TTR between patients with a score of 0–1 and ≥ 2 but there was a significantly higher percentage of patients with a TTR ≥ 65% between groups (93.8% vs. 69.2%, p < 0.0001, respectively). The SAMe–TT2R2 score may assist in identifying patients with VTE likely to achieve good control (TTR ≥ 65%), but further investigation is required to determine the most suitable model for predicting warfarin control in this population.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Wilbur J, Shian B (2017) Deep venous thrombosis and pulmonary embolism: current therapy. Am Fam Physician 95(5):295–302

    PubMed  Google Scholar 

  2. Bauer KA (2013) Pros and cons of new oral anticoagulants. Haematology 2013(1):464–470

    Google Scholar 

  3. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352

    PubMed  Google Scholar 

  4. Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A et al (2019) New guidelines from the thrombosis and haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 210(5):227–235

    PubMed  Google Scholar 

  5. Harder S, Graff J (2013) Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69(9):1617–1633

    CAS  PubMed  Google Scholar 

  6. Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335(8):540–546

    CAS  PubMed  Google Scholar 

  7. Schmitt L, Speckman J, Ansell J (2003) Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 15(3):213–216

    CAS  PubMed  Google Scholar 

  8. Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B et al (2018) Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 154(5):1121–1201

    PubMed  Google Scholar 

  9. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H et al (2014) New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 44(6):525–536

    CAS  PubMed  Google Scholar 

  10. Apostolakis S, Sullivan RM, Olshansky B, Lip GY (2013) Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest J 144(5):1555–1563

    CAS  Google Scholar 

  11. van Miert JH, Bos S, Veeger NJ, Meijer K (2018) Clinical usefulness of the SAMe–TT2R2 score: A systematic review and simulation meta-analysis. PLoS ONE 13(3):e0194208

    PubMed  PubMed Central  Google Scholar 

  12. Zulkifly H, Lip GY, Lane DA (2018) Use of the SAMe–TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: a review. Heart Rhythm 15(4):615–623

    PubMed  Google Scholar 

  13. Palareti G, Antonucci E, Lip GY, Testa S, Guazzaloca G, Falanga A et al (2016) The SAME–TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. Thromb Haemost 115(6):1101–1108

    PubMed  Google Scholar 

  14. Pivatto Júnior F, Scheffel RS, Ries L, Wolkind RR, Marobin R, Barkan SS et al (2017) SAMe–TT2R2 score in the outpatient anticoagulation clinic to predict time in therapeutic range and adverse events. Arq Bras Cardiol 108(4):290–296

    PubMed  PubMed Central  Google Scholar 

  15. Demelo-Rodríguez P, Postigo-Esteban A, García-Fernández-Bravo I, Agud M, Calpena S, Camacho M et al (2016) Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists. Thromb Res 147:58–60

    PubMed  Google Scholar 

  16. Kataruka A, Kong X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J et al (2017) SAMe–TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: the MAQI2 experience. Vasc Med 22(3):197–203

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Health Do. Guidelines for warfarin management in the community. Queensland: state of Queensland (Queensland Health) and the Royal Flying Doctor Service Queensland Section; Sep 2012. p. 23.

  18. Rosendaal F, Cannegieter S, Van der Meer F, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236–239

    CAS  PubMed  Google Scholar 

  19. Bernaitis N, Badrick T, Anoopkumar-Dukie S (2018) Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia. Int J Clin Pract 72(3):e13051

    PubMed  Google Scholar 

  20. Bernaitis N, Badrick T, Davey AK, Anoopkumar-Dukie S (2016) Quality of warfarin control in atrial fibrillation patients in South East Queensland. Aust Intern Med J 46(8):925–931

    CAS  Google Scholar 

  21. Bernaitis N, Clark G, Kohja S, Leong S, Anoopkumar-Dukie S (2019) The SAMe–TT2R2 score Predicts warfarin control in an Australian population with atrial fibrillation. J Clin Med 8(6):882

    CAS  PubMed Central  Google Scholar 

  22. Gallego P, Roldán V, Marin F, Gálvez J, Valdés M, Vicente V et al (2014) SAMe–TT 2 R 2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 127(11):1083–1088

    PubMed  Google Scholar 

  23. Skov J, Bladbjerg E-M, Bor MV, Gram J (2014) SAMeTT2R2 does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 145(1):187–188

    PubMed  Google Scholar 

  24. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ (2005) Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest J 127(5):1515–1522

    Google Scholar 

  25. Nichol MB, Knight TK, Dow T, Wygant G, Borok G, Hauch O et al (2008) Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 42(1):62–70

    PubMed  Google Scholar 

  26. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE (2002) Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 113(1):42–51

    PubMed  Google Scholar 

  27. Fauchier L, Poli D, Olshansky B (2015) The SAMe–TT2R2 score and quality of anticoagulation in AF: can we predict which patient benefits from anticoagulation? Thromb Haemost 114(4):657–659

    PubMed  Google Scholar 

  28. Pastori D, Pignatelli P, Cribari F, Carnevale R, Saliola M, Violi F et al (2018) Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists–naive patients with atrial fibrillation. Am Heart J 200:32–36

    CAS  PubMed  Google Scholar 

  29. Mueller K, Bernaitis N, Badrick T, Anoopkumar-Dukie S (2017) HAS-BLED Predicts Warfarin control in Australian patients treated for deep vein thrombosis. Basic Clin Pharmacol Toxicol 120(3):299–302

    CAS  PubMed  Google Scholar 

  30. Rivera-Caravaca JM, Viedma-Viedma I, Roldan V (2017) Factors affecting the quality of anticoagulation with vitamin K antagonists in venous thromboembolism patients. Biol Res Nurs 19(2):198–205

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Sullivan Nicolaides pathology, particularly Michael Harrison and Robyn Coleman, for their co-operation with this research.

Funding

No funding was received for this study.

Author information

Affiliations

  1. Quality Use of Medicines Network, Griffith University, Gold Coast Campus, QLD, Australia

    Nijole Bernaitis & Shailendra Anoopkumar-Dukie

  2. School of Pharmacy and Pharmacology, Griffith University, Gold Coast Campus, QLD, 4222, Australia

    Nijole Bernaitis & Shailendra Anoopkumar-Dukie

  3. The Royal College of Pathologists of Australasia (RCPA) Quality Assurance Programs, New South Wales, Australia

    Tony Badrick

Authors
  1. Nijole Bernaitis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tony Badrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shailendra Anoopkumar-Dukie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nijole Bernaitis.

Ethics declarations

Conflict of interest

The authors Nijole Bernaitis, Tony Badrick, and Shailendra Anoopkumar-Dukie declares that they have no conflict of interest.

Ethical approval

This study was approved by the Human Research Ethics Committee at Griffith University (PHM/09/14/HREC) and was conducted in accordance with the tenets of the Declaration of Helsinki.

Informed consent

This study was a retrospective data analysis which met the conditions for a waiver of consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bernaitis, N., Badrick, T. & Anoopkumar-Dukie, S. The SAMe–TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia. J Thromb Thrombolysis 50, 614–618 (2020). https://doi.org/10.1007/s11239-020-02068-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-020-02068-w

Keywords

  • Anticoagulant
  • Warfarin
  • Deep vein thrombosis
  • Venous thromboembolism